

## Contents

Contents .....	I- VI
List of Tables .....	VII- XI
List of Figures .....	XII- XVIII
List of Abbreviations .....	XIX- XX
<b>Chapter 1. Introduction.....</b>	<b>1-10</b>
1.1 Oral drug delivery.....	1
1.2 Lipid Based Systems.....	1
1.2.1 Self Emulsifying Drug Delivery Systems (SEDDS).....	3
1.2.2. Nanoemulsion .....	4
1.3 Introduction to the drugs .....	5
1.4 Aims and Objectives.....	7
1.5 Hypothesis.....	7
1.6 Plan of work.....	8
<b>Chapter 2. Literature Review.....</b>	<b>11-62</b>
2.1 Oral Delivery .....	11
2.2. Lipid Based Drug Delivery Systems (LBDDS).....	11
2.3. Drug Delivery Systems Selected for Present Study .....	20
2.4. Experimental Design by Quality by Design Approach.....	39
2.5. Drug Profiles.....	41
2.6. Excipients Profile.....	54
2.7. Conclusion.....	54
<b>Chapter 3. Analytical Techniques.....</b>	<b>63-124</b>
3.1 Introduction.....	63
3.2 Materials.....	63
3.2.1 Instruments and software .....	64
3.2.2. Reagents / solutions.....	64
3.2.3. Mobile phase for HPLC of DE.....	66
3.2.4. Mobile phase for HPLC of NISO.....	66
3.3. Methods.....	66

3.3.1. Estimation of DE by UV spectrophotometric methods.....	66
3.3.2. Validation of UV spectrophotometric methods.....	67
3.3.3. Estimation of DE by HPLC method.....	69
3.3.4. Estimation of DE in plasma by HPLC method.....	70
3.3.5. Validation of HPLC method.....	71
3.3.6. Estimation of NISO by UV spectrophotometric methods.....	71
3.3.7. Validation of UV spectrophotometric methods.....	72
3.3.8. Estimation of NISO by HPLC method.....	72
3.3.9. Estimation of NISO in plasma by HPLC method.....	73
3.3.10. Validation of HPLC method.....	74
3.4. Results and Discussion.....	74
3.4.1. Estimation of DE by UV spectrophotometry.....	74
3.4.2. Validation of UV spectrophotometric methods.....	76
3.4.3. Estimation of DE by HPLC method.....	88
3.4.4. Estimation of DE in plasma by HPLC method.....	93
3.4.5. Estimation of NISO by UV spectrophotometry.....	97
3.4.6. Estimation of NISO by HPLC method.....	112
3.4.7. Estimation of NISO in plasma by HPLC method.....	117
3.5. Conclusion.....	121

**Chapter 4 – Part A. Formulation Development (SMEDDS): Experimental ....125-138**

4.1. Materials and Equipments .....	125
4.1.1 Materials .....	125
4.1.2 Equipments.....	125
4.2. Preformulation.....	126
4.2.1 Authentication of drugs: Dabigatran etexilate and Nisoldipine.....	126
4.2.2 Drug-Excipients compatibility study .....	126
4.3. Fabrication of SMEDDS.....	127
4.3.1. Selection of oil phase by solubility studies.....	127
4.3.2. Selection of surfactant and cosurfactant by emulsification and solubility test.....	127
4.3.3. Establishment of pseudo ternary phase diagram .....	127
4.3.4. Preparation of DE and NISO SMEDDS.....	128

4.3.5. Optimization of DE-SMEDDS using D-optimal design and NISO-SMEDDS using 3 level factorial design.....	128
4.4. Characterization of DE-SMEDDS and NISO-SMEDDS.....	131
4.4.1. Robustness to dilution test.....	131
4.4.2. Thermodynamic stability studies.....	131
4.4.3. Globule size, poly dispersibility index (PDI) and zeta-potential.....	131
4.4.4. % Transmittance.....	132
4.4.5. Cloud point measurement.....	132
4.4.6. Viscosity.....	132
4.4.7. Self emulsification time and precipitation assessment.....	132
4.4.8. Morphological examination using Transmission Electron Microscopy (TEM).....	132
4.4.9. Drug content.....	133
4.4.10. Fourier transform infrared (FTIR) spectroscopy.....	133
4.4.11. Drug release studies.....	133
4.5. Stability study.....	136

**Chapter 4 – Part B. Formulation Development (SMEDDS): Results and Discussion**  
.....**139-190**

4.6. Preformulation.....	139
4.6.1. Authentication of drugs: Dabigatran etexilate and Nisoldipine.....	139
4.6.2 Drug-Excipients compatibility study.....	143
4.7. Fabrication of SMEDDS.....	148
4.7.1. Selection of oil phase by solubility studies.....	148
4.7.2. Selection of surfactant and cosurfactant by emulsification and solubility test.....	149
4.7.3. Establishment of pseudo ternary phase diagram .....	152
4.7.4. Optimization of DE-SMEDDS using D-optimal design .....	155
4.7.5. Optimization of NISO-SMEDDS using 3 level factorial design.....	160
4.8. Characterization of DE-SMEDDS and NISO-SMEDDS.....	167
4.8.1. Robustness to dilution test.....	167
4.8.2. Thermodynamic stability studies.....	168
4.8.3. Globule size, polydispersity index (PDI) and zeta-potential.....	169
4.8.4. % Transmittance.....	172

4.8.5. Cloud point measurement.....	172
4.8.6. Viscosity.....	172
4.8.7. Self emulsification time and precipitation assessment.....	173
4.8.8. Morphological examination using Transmission Electron Microscopy (TEM) .....	173
4.8.9. Drug content.....	174
4.8.10. Fourier transform infrared (FTIR) spectroscopy.....	175
4.8.11. Drug release studies.....	175
4.9 Stability study.....	185
<b>Chapter 5 – Part A. Formulation Development (NE): Experimental .....</b>	<b>191-197</b>
5.1. Materials and Equipments.....	191
5.1.1 Materials .....	191
5.1.2 Equipments.....	191
5.2. Fabrication of Nanoemulsion (NE).....	192
5.2.1. Selection of oil phase .....	192
5.2.2. Selection of Smix system.....	192
5.2.3. Procedure for fabrication of NE.....	192
5.3. Optimization of formulation components for the preparation of pre-emulsion using high speed homogenizer .....	193
5.4. Optimization of process parameters for the preparation of pre-emulsion using high speed homogenizer .....	193
5.5. Optimization of DE NE and NISO NE by full factorial design.....	193
5.6. Characterization of optimized batch of DE NE and NISO NE.....	195
5.6.1. Globule size, poly dispersity index (PDI) .....	195
5.6.2. Measurement of Zeta potential.....	195
5.6.3. Drug content.....	196
5.6.4. pH .....	196
5.6.5. Morphological examination using Transmission Electron Microscopy (TEM).....	196
5.6.6. Conductivity.....	196
5.6.7. Viscosity.....	196
5.6.8. Thermodynamic stability assessment .....	197
5.6.9. Fourier transform infrared (FTIR) spectroscopy.....	197

5.6.10. Drug release studies.....	197
5.7. Stability study.....	197

**Chapter 5 – Part B. Formulation Development (NE):Results and Discussion.199-235**

5.8. Optimization of formulation components for the preparation of pre-emulsion using high speed homogenizer .....	199
5.9. Optimization of process parameters for the preparation of pre-emulsion using high speed homogenizer (ultra turrax).....	200
5.10. Optimization of DE NE and NISO NE by full factorial design .....	202
5.10.1. Optimization of DE NE .....	202
5.10.2. Optimization of NISO NE.....	207
5.11. Characterization of optimized DE and NISO NE.....	214
5.11.1. Globule size, poly dispersity index (PDI) .....	214
5.11.2. Measurement of Zeta potential.....	215
5.11.3. Drug content.....	217
5.11.4. pH.....	217
5.11.5. Morphological examination using Transmission Electron Microscopy (TEM).....	217
5.11.6. Conductivity .....	218
5.11.7. Viscosity.....	218
5.11.8. Thermodynamic stability assessment.....	218
5.11.9 Fourier transform infrared (FTIR) spectroscopy.....	219
5.11.10. Drug release studies.....	223
5.12. Stability study.....	231

**Chapter 6 – Cell Line Studies.....236-252**

6.1. Introduction.....	236
6.2. Materials and Methods.....	236
6.2.1. Materials.....	236
6.2.2. Methods.....	237
6.3. Results and Discussion.....	240
6.3.1 Cell viability study .....	240
6.3.2. Cell uptake study by FACS.....	241
6.3.4. Cell permeability study using Transwell Insert.....	245

<b>Chapter 7 – <i>In Vivo</i> Studies.....</b>	<b>253-272</b>
7.1. Introduction.....	253
7.2. Methods.....	253
7.2.1. Protocol Approval.....	253
7.2.2. Animals.....	253
7.2.3. Pharmacokinetic Study of DE Formulations .....	254
7.2.4. Pharmacokinetic Study of NISO Formulations.....	255
7.2.5. Intestinal Lymphatic Transport Study of DE Formulations.....	255
7.2.6. Intestinal Lymphatic Transport Study of NISO Formulations.....	255
7.2.7. Pharmacodynamic Study of DE Formulations.....	255
7.2.8. Pharmacodynamic Study of NISO Formulations.....	256
7.3. Results and Discussion.....	258
7.3.1. Pharmacokinetic Study of DE Formulations.....	258
7.3.2. Pharmacokinetic Study of NISO Formulations.....	261
7.3.3. Intestinal Lymphatic Transport Study of DE Formulations.....	263
7.3.4. Intestinal Lymphatic Transport Study of NISO Formulations.....	265
7.3.5. Pharmacodynamic Study of DE Formulations.....	267
7.3.6. Pharmacodynamic Study of NISO Formulations.....	267
7.4. Conclusion.....	269
<b>Chapter 8. Summary and Conclusions.....</b>	<b>273-287</b>
8.1. Aim of present study.....	273
8.2. Preformulation.....	274
8.3. Analytical Method Development.....	274
8.4. Formulation development of SMEDDS for DE and NISO.....	276
8.5. Formulation development of NE for DE and NISO.....	277
8.6.Characterization of optimized DE and NISO-SMEDDS.....	279
8.7. Characterization of optimized DE and NISO NE.....	282
8.8. Cell line studies.....	284
8.9. <i>In vivo</i> studies .....	285
<b>Appendix I.....</b>	<b>I-V</b>
<b>Appendix II.....</b>	<b>VI-VIII</b>